Adalimumab Biosimilars Demonstrate Efficacy, Safety in Psoriasis Treatment

At week 16, no significant differences in response rates were observed regarding the adalimumab biologic and biosimilars.

Related Keywords

China ,Wanfang ,Jiangxi ,Chinese , ,Cochrane Library ,China National Knowledge Internet ,Psoriasis Area ,Severity Index ,